

Factors associated with onchocerciasis transmission after 20 years of community treatment with ivermectin in savanah and forest areas in Central African Republic : A Cross Sectional Study

Sylvain Honoré Woromogo^{1,2*¶}, Stéphanie Inesse Garoua-Adjou^{1¶}, Ange Donatien Ben Ngouyombo^{1¶}, Rodrigue Herman Doyama-Woza^{2¶}, Henri Saint Calvaire Diemer^{2¶}, Jean de Dieu Longo^{2¶}

¹Doctoral School of Human and Veterinary Sciences, University of Bangui, Central African Republic

²Department of Public Health, Faculty of Health Sciences, University of Bangui, Central African Republic

***Corresponding author:**

Dr. Sylvain Honore WOROMOGO

Doctoral School of Human and Veterinary Sciences, University of Bangui, Central African Republic

Phone (or Mobile) No.: +236 74 42 26 36

Email: woromogos@gmail.com

¶ These authors contributed equally to this work.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

The Central African Republic has endemic onchocerciasis in 20 health districts in savannah and forest areas. The country organised a mass distribution campaign of ivermectin in 2023 through the National Onchocerciasis Control Programme. The objectives of this study were to identify factors of persistent transmission of onchocerciasis. A cross-sectional study was carried out in Bossangoa (savannah area) and Kémo (forest area) health districts. Using kelsey's formula 1600 respondents were recruited. Dependent variable is onchocerciasis status. Bivariate analysis was carried out to determine the differential risks for onchocerciasis infection, each variable being taken separately. The strength of statistical associations was measured by prevalence rates (PR) from log-binomial regression model and their 95% confidence intervals. Onchocerciasis prevalence is 26.45% in Bossangoa (95% CI = 23.76 - 29.14), and 14.79% (84/568) in Kémo (95% CI = 23.53 - 29.37). In both savannah and forest areas, the common factors incriminated in the transmission of onchocerciasis after several years of community distribution of ivermectin are: young age (PR = 2.44 (1.97 – 3.03), $p < 0.001$; 3.63 (2.32 – 5.70), $p < 0.001$ respectively), not taking ivermectin (PR = 2.31 (1.86 – 2.87), $p < 0.001$; 6.84 (4.42 – 10.57), $p < 0.001$ respectively), male sex (PR = 2.54 (2.04 – 3.16), $p < 0.001$; 1.79 (1.19 – 2.69), $p = 0.002$ respectively), living near rivers and in rural areas. Despite efforts, the prevalence of onchocerciasis remains high in the 2 districts. The main factors incriminated in the persistence of transmission are failure to take ivermectin, male sex and young age. The National Onchocerciasis Control Programme needs to review its planning of activities, ensuring that the population is constantly made aware before drugs are distributed, and increasing the number of days of community-based distribution in order to improve therapeutic coverage.

Key words : Burden, Transmission, Factors, Onchocerciasis, Savannah, Forest

Synopsis

Onchocerciasis is a disease called River Blindness and transmitted by the bites of infected blackflies that reproduction is in high-flow streams. This disease affects the skin (itching and nodules) and eyes (redness and even blindness). An effective treatment is ivermectin. Human activities near rivers contribute to the disease. Also, good coverage of ivermectin intake by the population considerably reduces the number of people affected. The question we asked ourselves was: why, after more than 20 years of community-based distribution of ivermectin in the Central African Republic, is onchocerciasis still being transmitted? The Central African Republic has made considerable efforts to combat onchocerciasis despite the war, but the number of people infected remains high. The study showed that in both the savannah and the forest, men are particularly at risk, not only because of their activities near rivers, but also because they do not protect their bodies as women do. We found a higher number of people affected in rural areas than in urban areas. In the community that adheres to ivermectin use, the number of people affected decreases. We recommended that the national onchocerciasis control programme take into account the habits of the population in order to plan and monitor their control activities (for example: increase the number of days ivermectin is distributed, and the number of days community awareness is raised).

Introduction

Onchocerciasis or river blindness is a parasitic disease caused by the threadworm *Onchocerca volvulus* (1). This worm is transmitted to humans by the bites of infected simuliids (or black flies) and reproduces in high-flow streams (rivers). The adult worm produces embryonic larvae (microfilariae) in the human body, which migrate into the skin, eyes and other organs. When a female black fly bites an infected person to feed on their blood, it also absorbs microfilariae which reproduce in the black fly and are then transmitted to other humans who are bitten (2).

Onchocerciasis leads to eye and skin complications (3). A genuine public health problem in terms of morbidity, onchocerciasis is observed in three WHO regions: the African Region, the American Region and the Eastern Mediterranean Region. In Africa, onchocerciasis affects twenty-seven countries, and more than 99% of infected people live in sub-Saharan Africa (4). According to the global burden of disease study estimate, there were 20.9 million *O. volvulus* infections worldwide in 2017; 14.6 million of the infected people had skin disease and 1.15 million had vision loss (5,6). From a socio-economic point of view, although the impact of the infestation on longevity is controversial, a study carried out in the West African savannah showed a 13-year reduction in the life expectancy of blind people compared with non-blind people (2). Some of the consequences of this disease on the lives of people in endemic areas remain a cause for concern (3,4,7–9).

Treatment of individuals with ivermectin for 10 to 15 years through Mass Drug Administration (MDA) programs annually or biannually was suggested by the African Program for Onchocerciasis Control (APOC) as a means for disease elimination because the ivermectin kills the microfilaria but only partly paralyzes the adult worm, and must be taken for the reproductive lifespan of the worm to counteract transmission (10). APOC ended in 1995, and individual countries were responsible for ensuring disease elimination (11). In the African region, treatment increased from 119 million in 2015 to 132 million in 2016, and therapeutic coverage rose from 64% to 67% (4).

The Central African Republic (CAR) has endemic onchocerciasis in 20 health districts in savannah and forest areas. Supported by several partners, the country has organised a mass distribution campaign of ivermectin in 2023 through the National Onchocerciasis Control Programme (PNLOC). One year after this campaign, we wanted to measure the prevalence of the disease in 2 health districts, one in the savannah zone and the other in the forest zone, and to identify the factors that transmit the disease, with the aim of helping to reduce morbidity due to this Neglected Tropical Disease (NTD).

Methods

Study setting

The study was conducted in 2 endemic health districts in the Central African Republic: Bossangoa in the savannah zone and Kémo in the forest zone. These 2 health districts are bordered by rivers with confluences, with a total population of 175,679 and 193,044 respectively. The main activities in common in these 2 areas are trade, agriculture, breeding, hunting and other informal activities. We chose these 2 districts because a mass ivermectin distribution campaign was organised in 2023, with therapeutic coverage of 45% and 81% respectively in Bossangoa and Kémo. Furthermore, members of the management team in these 2 health districts received training in the diagnosis of Neglected Tropical Diseases in the same year, with the support of partners (WHO, cbm and MDP).

Study design and participants

We conducted a cross-sectional analytical study from 4 January to 30 March 2024. Participants were residents of Bossangoa and Kémo health districts. Anyone over 5 years of age who had been resident in the locality for at least one year and who agreed to take part in the study was included. Participants under 5 years of age, those who had been resident for less than a year and those who refused to take part in the study were excluded. Anyone over 5 years of age who had been resident in the locality for at least one year and who agreed to take part in the study was included. Participants under 5 years of age, those who had been resident for less than a year and those who refused to take part in the study were excluded. For participants under the age of 15, verbal parental consent is required. The WHO recommends including children under the age of 10, believing that this is the best way to assess active transmission of the infection (12).

Sampling

The sample size for this study was determined using Kelsey's formula in STAC Calc from EpiInfo for an observational study, for a power of 80%, a ratio of unexposed to exposed of 2 and a 95% confidence interval.(13). Considering a non-response rate of 10%, the final sample size is 1600 participants.

We used a cluster survey to obtain respondents. The clusters were formed from a list of all the villages and neighbourhoods in each health district. This gave us 30 clusters per health district. For each cluster selected, all eligible participants were included in the study. In order to get as many respondents as possible in a cluster or village, awareness-raising sessions were held with

village chiefs a week before the survey date. On the survey day, the team explained the purpose of the study to each participant in an information note and obtained informed consent, which was read and signed before the questionnaire was administered, followed by a clinical examination and skin samples.

Variables

The dependent variable was the presence or absence of onchocerciasis. For this study we collected as independent variables i) sociodemographic data (age, sex, occupation, activities, residence, duration of residence of respondents, ii) clinical and medical data (skin and eye characteristics, duration of signs, ivermectin intake).

Data collection and tools

A structured questionnaire, pre-tested in another health district and validated, was used to collect data. It was administered in French and Sango (CAR's other national language) by members of the district team, 6th year medical students and 3rd year nursing students. Members of the health district team who had been trained in onchocerciasis diagnosis briefed the other investigators.

Prevalence of onchocerciasis is determined by individual and community diagnosis. For individual diagnosis, a skin sample (bloodless skin biopsy) is taken and examined for microfilariae, and experienced investigators have used a slit lamp to look for microfilariae in the eye. Dermal microfilariae were detected by examination of the bloodless skin biopsy using Holth 2.3 mm snip forceps. Two samples were collected from the iliac crests, one on the right, the other on the left, and then placed in the wells of a microtiter plate after adding a drop of distilled water. Then the plates covered with parafilm paper. The samples were read within 24 hours of incubation.

Community diagnosis is epidemiological: symptoms of the disease in skin and eyes. For the questions analyzing skin changes, any positive reports from the respondents were checked clinically and confirmed by the interviewer. For epilepsy and seizures, the inter-viewer made sure the definition of the condition was clear to the respondent, describing the disease in simple words and with example. Diagnosed respondents are treated.

Data analysis

Anonymised data were entered into an Excel® file and analysed using EpiInfo™ software version 3.5.1. Independent and dependent variables were summarized using descriptive

statistics, which were reported as frequencies and proportions for qualitative variables and mean with standard deviation for quantitative variables. The chi-square test was used to compare categorical variables with a significance level of $p < 0.05$.

For each variable taken separately, the results were first given according to the onchocerciasis status. Thereafter, bivariate analysis was carried out to determine the differential risks for onchocerciasis infection, each variable being taken separately. The strength of statistical associations was measured by prevalence rates (PR) from log-binomial regression model and their 95% confidence intervals.

Ethical considerations

The study protocol was validated by the Ethics Committee of the Faculty of Health Sciences of the University of Bangui (« CSCVPER ») (agreement UB/-FACSS/CSCVPER). Each participant read and understood the information note for the study. Signed informed consent was obtained from each respondent. Formal written consent was obtained from the parents/guardian for children under the age of 18. Finally, all respondents received a commitment that their data would be anonymised.

Results

Baseline characteristics of respondents

Of the 1600 respondents, 1032 were from Bossangoa health district and 568 from Kémo health district. The average age of participants was 31.22 years (± 6.46). More than half of the respondents work in the informal sector (fishing, hunting, agriculture, etc.). At least 60% of participants lived in rural areas and just under half lived along rivers (763/1600). Some respondents acknowledged that they had not taken ivermectin during the last distribution campaign (610/1600). Table 1 shows the other characteristics of the participants.

Prevalence and symptoms of onchocerciasis among respondents

Among the 1600 respondents examined, 357 had onchocerciasis, representing a prevalence of 22.31% (95% CI = 20.27 - 24.35). At health district level, this prevalence is 26.45% (273/1032) in Bossangoa (95% CI = 23.76 - 29.14), and 14.79% (84/568) in Kémo (95% CI = 23.53 - 29.37). The signs and symptoms of onchocerciasis observed among respondents are presented in Table 2.

Ivermectin uptake and onchocerciasis status

Onchocerciasis is common in children aged between 5 and 14 and in the 15-34 age group in our context. Of the 367 men taking ivermectin in 2023, 208 (56.67%) were positive for onchocerciasis (compared with 23.92% of women). Among respondents who had taken ivermectin in a single year, 44.63% (291/652) were positive for onchocerciasis, whereas among those who had taken ivermectin for more than 2 years, 19.53% (66/338) were positive. A significant association was found between not taking ivermectin and positive onchocerciasis status ($p < 0.001$)(Table 3).

Factors associated of transmission

In both savannah and forest areas, the common factors incriminated in the transmission of onchocerciasis after several years of community distribution of ivermectin are: young age (PR = 2.44 (1.97 – 3.03), $p < 0.001$; 3.63 (2.32 – 5.70), $p < 0.001$ respectively), not taking ivermectin (PR = 2.31 (1.86 – 2.87), $p < 0.001$; 6.84 (4.42 – 10.57), $p < 0.001$ respectively), male sex (PR = 2.54 (2.04 – 3.16), $p < 0.001$; 1.79 (1.19 – 2.69), $p = 0.002$ respectively), living near rivers and in rural areas. In forested areas, profession plays no role in onchocerciasis transmission, and living in a rural environment appears to protect against onchocerciasis transmission (PR = 0.33 (0.21 - 0.50), $p < 0.001$) (Tables 4 and 5).

Discussion

The relevance of the study

Neglected tropical diseases in general, and onchocerciasis in particular, are a real public health concern, not only because of their persistent prevalence, but also because of their gravity, since millions of infected people have a disability-adjusted life years (14). It is in this context that countries have benefited from the support of numerous partners such as WHO which published NTD Roadmap for 2021–2030 for elimination of transmission (EOT) for onchocerciasis, with 12 countries (including CAR) proposed to be verified for EOT by 2030 (15). A number of statements supported this vision (16–19).

The CAR has signed up to these declarations and has an obligation to achieve results, as the selected indicators for SDG 3 include those relating to NTDs, particularly target 3.3. Onchocerciasis in CAR has long been considered a curse, especially in the town of Bossangoa, which is reputed to be host to a record number of blind people due to onchocerciasis. The town's beggars are precisely these blind people, despite receiving aid from charitable associations.

This study showed that the population is young and needs to be protected : average age of was 31.22 years (\pm 6.46). Several authors reported the same trends (20–22). Over 60.69% (671/1600) of the population studied live in rural areas and 38.12% (610/1600), which means that strategies need to be developed to reach people in remote areas.

Real burden as neglected tropical disease

Despite several years of efforts to combat onchocerciasis, prevalence remains high in these 2 districts (22.31% [95% CI = 20.27 - 24.35] in Bossangoa district and 14.79% [95% CI = 23.53 - 29.37] in Kémo district. whereas in Cameroon this prevalence is relatively low, varying from 1.5 to 6% (23), and Guinea, which will be ready for 2030 (24). WHO recommends that countries eliminate onchocerciasis with a prevalence of 0.1% (11). The Central African Republic is one of the countries that have made progress in onchocerciasis control and elimination (11,14), but more needs to be done if it is to meet the 2030 target. The country's nationwide civil war since 2013 has had a detrimental effect on the elimination of onchocerciasis. Some studies have pointed to this aspect (11). Participants examined showed the classic signs of skin and eye damage, with an impressive number of blind people (401 in total). A number of respondents, 99/600 (6.19) have onchocerciasis-associated epilepsy (OAE) status. Similar proportions were observed in the Democratic Republic of Congo and South Sudan (25,26). This may explain the high density of microfilariae in the body. These people may be stigmatised by the public, which could prevent them from being married (27).

Transmission factors

The prevalence was significantly higher in men compared to women and was associated with younger age groups. The particularity of the Kémo health district is that this difference is not significant for the 15-34 age group. In this district, secondary school instructors take part in the distribution of ivermectin in schools. In any event, this study showed the vulnerability of children to onchocerciasis (6) and that men are much more exposed to the bites of simuli than women, because women protect their bodies better than men and most activities near forests and rivers are carried out by men. In Bossangoa district as in Kémo district, we can find many activities in the forests and around rivers that expose people to the black flies propagate continued transmission. Proximity to rivers breeding sites for the vector have been described to influence the continued transmission of onchocerciasis by increasing exposure. Failure to take ivermectin during distribution campaigns is associated with positive onchocerciasis status. Low ivermectin intake was identified as a factor in the transmission of the disease. Several authors

have attested to this fact (28). So it is importance of improving and sustaining high therapeutic coverage and increasing treatment frequency if countries are to achieve elimination of onchocerciasis transmission.

Strengths and limitations of study

This study is not a comparison of prevalence between two onchocerciasis endemic areas, one in the savannah and the other in the forest. It highlighted the particularities of transmission of the disease in each of these regions, which should be taken into account in the planning of control activities by the PNLOC. In addition, this study did not describe the reasons why participants did not take ivermectin; this was taken into account in another study.

Conclusions

After more than 20 years of combating onchocerciasis through the community-based distribution of ivermectin, the prevalence of this disease remains worrying in both savannah and forest areas: 26.45% and 14.79% respectively. This prevalence is reduced when the population adheres to taking ivermectin. The burden of onchocerciasis in endemic areas is evident in skin and eye disorders. The main factors in the transmission of the disease in these two areas are young age, male sex, not taking ivermectin and living near rivers. The PNLOC needs to review its planning of activities, ensuring that the population is constantly made aware before drugs are distributed, and increasing the number of days of community-based distribution in order to improve therapeutic coverage. Finally, all activities need to be monitored and evaluated.

Acknowledges

We would like to thank the members of the health management teams in these 2 health districts, the health centre managers in these districts and the leaders of these 2 communities who helped to make this study a success.

Authors contribution

WSH designed the study, wrote the protocol and text and supervised the data analysis. SHW, SIGA, ADBN, RHDW, HSCD and JDDL participated in the drafting of the protocol, data analysis and text writing. WSH coordinated all stages of the research. All authors have read and approved the manuscript and contributed equally.

Conflicts of interest

No conflicts

References

1. Onchocercose [Internet]. [cited 2024 Jun 9]. Available from: <https://www.who.int/fr/news-room/fact-sheets/detail/onchocerciasis>
2. Onchocerciasis (River Blindness) - Infectious Diseases - MSD Manual Professional Edition [Internet]. [cited 2024 Jun 23]. Available from: <https://www.msmanuals.com/professional/infectious-diseases/nematodes-roundworms/onchocerciasis-river-blindness>
3. Kirkwood B, Smith P, Marshall T, Prost A. Relationships between mortality, visual acuity and microfilarial load in the area of the Onchocerciasis Control Programme. *Trans R Soc Trop Med Hyg* [Internet]. 1983 [cited 2024 Jun 23];77(6):862–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/6665841/>
4. Guderian RH, Lovato R, Anselmi M, Mancero T, Cooper PJ. Onchocerciasis and reproductive health in Ecuador. *Trans R Soc Trop Med Hyg* [Internet]. 1997 [cited 2024 Jun 23];91(3):315–7. Available from: <https://pubmed.ncbi.nlm.nih.gov/9231206/>
5. World Health Organization. L'onchocercose et la lutte anti-onchocerquienne : rapport. 1995;113.
6. Mshana MI, Silvestri V, Mushi V, Bonaventura WM, Tarimo D, Ngasala B, et al. Burden and factors associated with onchocerciasis transmission among school-aged children after more than 20 years of Community Directed Treatment with Ivermectin in Ulanga district, Tanzania: A school-based cross-sectional study. *PLOS Glob Public Heal*. 2023 May 12;3(5):e0001919.
7. Evans TG. Socioeconomic consequences of blinding onchocerciasis in west Africa. *Bull World Health Organ* [Internet]. 1995 [cited 2024 Jun 23];73(4):495. Available from: <https://pubmed.ncbi.nlm.nih.gov/1044444/>
8. Sherwin JC, Lewallen S, Courtright P. Blindness and visual impairment due to uncorrected refractive error in sub-Saharan Africa: Review of recent population-based studies. *Br J Ophthalmol*. 2012 Jul;96(7):927–30.
9. Ahmed A, Elbashir A, Mohamed AA, Alim AA, Mubarak A, Abdelrahman D, et al. Socioeconomic impacts of elimination of onchocerciasis in Abu-Hamed focus, northern Sudan: Lessons after elimination. *BMC Res Notes*. 2020 May 26;13(1).
10. Colebunders R, Njamnshi AK, Menon S, Newton CR, Hotterbeekx A, Preux PM, et al. Onchocerca volvulus and epilepsy: A comprehensive review using the Bradford Hill criteria for causation. *PLoS Negl Trop Dis* [Internet]. 2021 Jan 1 [cited 2024 Jun 23];15(1):1–24. Available from: <https://pubmed.ncbi.nlm.nih.gov/3381111/>
11. Lakwo T, Oguttu D, Ukety T, Post R, Bakajika D. Onchocerciasis Elimination: Progress and Challenges. *Res Rep Trop Med* [Internet]. 2020 Oct [cited 2024 Jun 23];11:81. Available from: <https://pubmed.ncbi.nlm.nih.gov/3381111/>
12. Hendy A, Krüger A, Pfarr K, De Witte J, Kibweja A, Mwingira U, et al. The blackfly vectors and transmission of Onchocerca volvulus in Mahenge, south eastern Tanzania.

- Acta Trop [Internet]. 2018 May 1 [cited 2024 Jun 20];181:50–9. Available from: <https://pubmed.ncbi.nlm.nih.gov/29410302/>
13. Kelsey JL. Methods in Observational Epidemiology; Table 12-15 \r. Results from OpenEpi, Version 3, open source Calc [Internet]. 1996 [cited 2024 Jun 20];10:366 pages. Available from: <https://search.worldcat.org/title/856808377>
14. Abbafati C, Abbas KM, Abbasi M, Abbasifard M, Abbasi-Kangevari M, Abbastabar H, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet (London, England) [Internet]. 2020 Oct 17 [cited 2024 Mar 12];396(10258):1204–22. Available from: <https://pubmed.ncbi.nlm.nih.gov/33069326/>
15. Ending the neglect to attain the Sustainable Development Goals: A road map for neglected tropical diseases 2021–2030 [Internet]. [cited 2024 Jun 24]. Available from: <https://www.who.int/publications/i/item/9789240010352>
16. UNSDG | Leave No One Behind [Internet]. [cited 2024 Jun 24]. Available from: <https://unsdg.un.org/2030-agenda/universal-values/leave-no-one-behind>
17. Turner HC, Walker M, Churcher TS, Osei-Atweneboana MY, Biritwum NK, Hopkins A, et al. Reaching the London Declaration on Neglected Tropical Diseases Goals for Onchocerciasis: An Economic Evaluation of Increasing the Frequency of Ivermectin Treatment in Africa. Clin Infect Dis An Off Publ Infect Dis Soc Am [Internet]. 2014 Oct 10 [cited 2024 Mar 12];59(7):923. Available from: </pmc/articles/PMC4166981/>
18. The Kigali Declaration | Uniting to Combat NTDs [Internet]. [cited 2024 Mar 12]. Available from: <https://unitingtocombatntds.org/en/the-kigali-declaration/>
19. Elphick-Pooley T, Engels D. World NTD Day 2022 and a new Kigali Declaration to galvanise commitment to end neglected tropical diseases. Infect Dis poverty [Internet]. 2022 Dec 1 [cited 2024 Jun 24];11(1). Available from: <https://pubmed.ncbi.nlm.nih.gov/35086566/>
20. Mshana Id MI, Silvestri Id V, Id VM, Bonaventura WM, Tarimo D, Ngasala B, et al. Burden and factors associated with onchocerciasis transmission among school-aged children after more than 20 years of Community Directed Treatment with Ivermectin in Ulanga district, Tanzania: A school-based cross-sectional study. 2023 [cited 2024 Jun 13]; Available from: <https://doi.org/10.1371/journal.pgph.0001919>
21. Komlan K, Vossberg PS, Gantin RG, Solim T, Korbmacher F, Banla M, et al. Onchocerca volvulus infection and serological prevalence, ocular onchocerciasis and parasite transmission in northern and central Togo after decades of Simulium damnosum s.l. vector control and mass drug administration of ivermectin. PLoS Negl Trop Dis [Internet]. 2018 Mar 1 [cited 2024 Jun 10];12(3). Available from: <https://pubmed.ncbi.nlm.nih.gov/29494606/>
22. Otabil KB, Basáñez MG, Ankrah B, Bart-Plange EJ, Babae TN, Kudzordzi PC, et al. Non-adherence to ivermectin in onchocerciasis-endemic communities with persistent infection in the Bono Region of Ghana: a mixed-methods study. BMC Infect Dis [Internet]. 2023 Dec 1 [cited 2024 Jun 24];23(1). Available from: </pmc/articles/PMC10655298/>
23. Nyagang SM, Cumber SN, Cho JF, Keka EI, Nkfusai CN, Wepngong E, et al. Prevalence of onchocerciasis, attitudes and practices and the treatment coverage after

- 15 years of mass drug administration with ivermectin in the Tombel Health District, Cameroon. *Pan Afr Med J* [Internet]. 2020 [cited 2024 Jun 24];35. Available from: [/pmc/articles/PMC7321683/](https://pmc/articles/PMC7321683/)
24. Cherif MS, Keita M, Dahal P, Guilavogui T, Habib Beavogui A, Diassy L, et al. Neglected tropical diseases in Republic of Guinea: disease endemicity, case burden and the road towards the 2030 target. *Int Health* [Internet]. 2023 [cited 2024 Jun 24]; Available from: <https://doi.org/10.1093/inthealth/ihad036>
25. Siewe Fodjo JN, Mandro M, Mukendi D, Tepage F, Menon S, Nakato S, et al. Onchocerciasis-associated epilepsy in the Democratic Republic of Congo: Clinical description and relationship with microfilarial density. *PLoS Negl Trop Dis* [Internet]. 2019 Jul 1 [cited 2024 Jun 24];13(7). Available from: <https://pubmed.ncbi.nlm.nih.gov/31314757/>
26. Bhattacharyya S, Melchers NVSV, Fodjo JNS, Vutha A, Coffeng LE, Logora MY, et al. Onchocerciasis-associated epilepsy in Maridi, South Sudan: Modelling and exploring the impact of control measures against river blindness. *PLoS Negl Trop Dis* [Internet]. 2023 May 1 [cited 2024 Jun 24];17(5). Available from: <https://pubmed.ncbi.nlm.nih.gov/37235598/>
27. Jada SR, Tionga MS, Siewe Fodjo JN, Carter JY, Logora MY, Colebunders R. Community perception of epilepsy and its treatment in onchocerciasis-endemic villages of Maridi county, western equatoria state, South Sudan. *Epilepsy Behav* [Internet]. 2022 Feb 1 [cited 2024 Jun 24];127. Available from: <https://pubmed.ncbi.nlm.nih.gov/35026562/>
28. Forrer A, Wanji S, Obie ED, Nji TM, Hamill L, Ozano K, et al. Why onchocerciasis transmission persists after 15 annual ivermectin mass drug administrations in South-West Cameroon. *BMJ Glob Heal* [Internet]. 2021 Jan 1 [cited 2024 Jun 10];6(1):e003248. Available from: <https://gh.bmj.com/content/6/1/e003248>